Critical Outcome Advances To Fourth Cohort In Phase 1 Study of COTI-2 In Gynecologic Cancers

Critical Outcome Technologies Inc. (“COTI” or the “Company”) (TSX Venture: COT; OTCQB: COTQF), a clinical stage biotechnology company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has commenced dosing women in the fourth cohort of its ongoing Phase 1 clinical trial of COTI-2 intended for the treatment…

Critical Outcome Technologies Appoints Alison Silva as Chief Executive Officer

Critical Outcome Technologies Inc. (TSX Venture: COT; OTCQB: COTQF) (“COTI” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that its Board of Directors has appointed Alison Silva as the Company’s next Chief Executive Officer effective January 1, 2017. Ms. Silva, who currently…

Critical Outcome Technologies and Delmar Chemicals sign collaboration agreement

Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) and Delmar Chemicals Inc. (Delmar), a Canadian company owned by Holding F.I.S S.p.A announced today that they have entered into a research and development collaboration agreement to advance selected small molecules. COTI and Delmar will work together to discover, select, screen and synthesize compounds for targets that have been identified as…